NATRILIX®

indapamide

a primary antihypertensive agent

Natrilix offers a simple, effective means of controlling blood pressure both in newly diagnosed and in poorly controlled patients with mild to moderate hypertension

Prescribing information

Presentation
Pink biconvex sugar-coated tablets each containing 2.5 mg indapamide hemihydrate.

Uses
For the treatment of hypertension.

Dosage and administration

Adults
The dosage is one tablet daily to be taken in the morning.

Children
There is no experience of the use of this drug in children.

Contra-indications, warning, etc.
There are no absolute contra-indications to the use of Natrilix but caution should be exercised when prescribing it in cases of severe renal or hepatic impairment. As with all new drugs, the administration of Natrilix should be avoided during pregnancy although no teratological effects have been seen in animals. At doses higher than that recommended, Natrilix has a diuretic effect, therefore it is not recommended to prescribe it with a diuretic agent which may cause hypokalaemia. Also, slight weight loss has been reported in some patients taking Natrilix. Reported side effects have included nausea and headache, but they are generally uncommon and mild in nature.
Serum urate levels may rise slightly but there is no evidence that glucose tolerance is adversely affected.
Box of 30 tablets.
Product licence number 0093/0022.



NATRILIX is available as:
FLUDEX® in Africa, Belgium, France, Holland, Portugal, Switzerland.
NATRILIX® in English speaking Countries of Africa, Brazil, Central America, Germany, Ireland, Italy, Middle East, South East Asia, United Kingdom.
TERTENSIF® in Spain.
NATRIX® in Korea.

Further information is available on request from
Servier Laboratories Ltd.,
Servier House, Horsenden Lane South, Greenford, Middx.
UB6 7PW.

Les Laboratoires Servier,
22, rue Garnier - 92201 Neuilly - France.

one tablet daily

New strength tablet from Geigy

VOLTAROL® 50

diclofenac sodium

bridges the gap between efficacy and tolerability

Rheumatoid arthritis

Osteoarthritis

Simpler dosage for better patient compliance

Mode of action Voltarol is a non-steroidal agent with marked analgesic/anti-inflammatory and antipyretic properties. Like most other drugs in this class, it is an inhibitor of prostaglandin synthetase.

Indications Rheumatoid arthritis, osteoarthritis.

Dosage Severe cases: 1 x 50 mg tablet 3 times daily. Maintenance therapy: 1 x 50 mg tablet morning and evening may be sufficient.
Mild cases: Initially 1 x 25 mg tablet 3 times daily. Maintenance dosage should be adjusted to the minimum amount that will provide continuous therapeutic control.

Contraindications Peptic ulcer. Voltarol is contra-indicated in asthmatic patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other non-steroidal anti-inflammatory agents with prostaglandin synthetase inhibiting activity.

Precautions Voltarol should not be prescribed during pregnancy, unless there are compelling reasons for doing so. Patients with a history of peptic ulcer, haematemesis or melaena, or with severe hepatic or renal insufficiency, should be kept under close surveillance. Voltarol has been reported to depress salicylate levels and vice versa; the clinical relevance of this phenomenon is not yet known.

Warnings and side-effects Initially, some patients may complain of epigastric pain, nausea and diarrhoea, headache and slight dizziness. These side-effects are often transient, disappearing with continuation of medication. Occasionally skin rash, peripheral oedema and abnormalities of serum transaminases have been reported.
Very rarely peptic ulcer and haematemesis or melaena have been reported, mainly in patients with a history of such disorders, or who were receiving concomitant antirheumatic medication.

Accidental overdosage There is no known antidote to Voltarol and the treatment is symptomatic. Immediate treatment consists of forced emesis to recover undigested tablets.

Pharmaceutical precautions Storage – protect from moisture.

Legal category Prescription only.

Presentation Voltarol, sodium-[o-[(2, 6-dichlorophenyl)-amino]-phenyl]-acetate, is available as: yellow, round, slightly bi-convex, enteric coated tablets with bevelled edges, approximately 7 mm diameter, imprinted GEIGY on one side. Each tablet contains 25 mg.
Voltarol is also available as: light-brown, round, slightly bi-convex, enteric coated tablets with bevelled edges, approximately 8 mm diameter, imprinted GEIGY. Each tablet contains 50 mg.

Package quantities
Voltarol 25 mg Packs of 100.
Basic N.H.S. price £9.00.
Voltarol 50 mg Packs of 100.
Basic N.H.S. price £17.50.

Further information Pharmacodynamic studies have shown no potentiation of oral hypoglycaemic and anticoagulant drugs.

Product licence numbers
Tablets 25 mg. PL0001/0036.
Tablets 50 mg. PL0001/0082.

Product licence holder
Geigy Pharmaceuticals, Horsham, West Sussex.